IMD-0354 is a nuclear factor-kappaB (NF-κB) activation inhibitor potentially for the treatment of atopic dermatitis. IMD-0354 significantly reduces the accumulation of inflammation damage and oxidative lesions. Furthermore, IMD-0354 treatment could block IκBα degradation and suppress mRNA and protein level of nuclear factor (NF) -κB p65. IMD-0354. IMD-0354 exerts anti-asthmatic action, at least partially, by blocking the activation and clonal expansion of CD4(+) Teff cells in the MLNs, which, consequently, prevents infiltration of the lungs with activated CD4(+) Teff cells.
IκB/IKK Inhibitors Related Products:
Resveratrol; BAY 11-7082; IKK-16; TPCA-1; BMS-345541; BMS-345541 HCl; SC-514; LY2409881 trihydrochloride; Bardoxolone methyl; TBK1; WS6; WS3; MRT67307